[go: up one dir, main page]

WO2001035947A3 - Treating wasting syndromes with aryloxy propanolamines - Google Patents

Treating wasting syndromes with aryloxy propanolamines Download PDF

Info

Publication number
WO2001035947A3
WO2001035947A3 PCT/US2000/028889 US0028889W WO0135947A3 WO 2001035947 A3 WO2001035947 A3 WO 2001035947A3 US 0028889 W US0028889 W US 0028889W WO 0135947 A3 WO0135947 A3 WO 0135947A3
Authority
WO
WIPO (PCT)
Prior art keywords
group
treating
wasting syndromes
substituted
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/028889
Other languages
French (fr)
Other versions
WO2001035947A2 (en
Inventor
Deana Lori Hancock
Randall Bruce Hopkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to AU15727/01A priority Critical patent/AU1572701A/en
Publication of WO2001035947A2 publication Critical patent/WO2001035947A2/en
Publication of WO2001035947A3 publication Critical patent/WO2001035947A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Disclosed is a method of treating a subject with a Wasting Syndrome. The method comprising the step of administering to the subject an effective amount of a compound represented by Structural Formula (I), Ar is a substituted or unsubstituted aryl group. Ar is preferably a monocyclic heteroaryl group or a fused polycyclic heteroaryl group. Ring A has zero, one or more additional substituents. R1 and R2 are independently -H or a C1-C4 alkyl group. W is -CH2-, -CH2CH2- or -CH2CH2CH2-. R3 is a substituted or unsubstituted phenyl or pyridyl group.
PCT/US2000/028889 1999-11-15 2000-11-13 Treating wasting syndromes with aryloxy propanolamines Ceased WO2001035947A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU15727/01A AU1572701A (en) 1999-11-15 2000-11-13 Treating wasting syndromes with aryloxy propanolamines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16546499P 1999-11-15 1999-11-15
US60/165,464 1999-11-15

Publications (2)

Publication Number Publication Date
WO2001035947A2 WO2001035947A2 (en) 2001-05-25
WO2001035947A3 true WO2001035947A3 (en) 2001-11-22

Family

ID=22599002

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/028889 Ceased WO2001035947A2 (en) 1999-11-15 2000-11-13 Treating wasting syndromes with aryloxy propanolamines

Country Status (2)

Country Link
AU (1) AU1572701A (en)
WO (1) WO2001035947A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003514801A (en) 1999-11-15 2003-04-22 イーライ・リリー・アンド・カンパニー Indazolyloxypropanolamine for improving livestock production
CA2426730A1 (en) * 2000-10-25 2002-05-16 Smithkline Beecham Corporation Calcilytic compounds
IL154928A0 (en) 2000-11-10 2003-10-31 Lilly Co Eli 3-substituted oxindole beta 3 agonists
DE60211199T2 (en) 2001-08-14 2007-02-01 Eli Lilly And Co., Indianapolis 3-SUBSTITUTED OXINDOL BETA-3 AGONISTS
WO2003016307A1 (en) 2001-08-14 2003-02-27 Eli Lilly And Company β3 ADRENERGIC AGONISTS
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
ATE386740T1 (en) 2001-11-20 2008-03-15 Lilly Co Eli BETA-3 ADRENERGIC AGONISTS
EP1448560B1 (en) 2001-11-20 2005-06-15 Eli Lilly And Company 3-SUBSTITUTED OXINDOLE beta 3 AGONISTS
US7009060B2 (en) 2002-01-11 2006-03-07 Eli Lilly And Company 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists
EP1778638A1 (en) 2004-07-21 2007-05-02 Theravance, Inc. Diaryl ether beta2 adrenergic receptor agonists
EA201590446A1 (en) * 2012-10-02 2015-07-30 Эли Лилли Энд Компани WAYS TO INCREASE PRODUCTIVITY OF CHICKENS
GB202213163D0 (en) * 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1463219A (en) * 1974-04-03 1977-02-02 Roussel Uclaf Thyronamine derivatives
EP0140243A2 (en) * 1983-10-19 1985-05-08 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Phenoxypropanol amines
WO1994012166A1 (en) * 1992-11-26 1994-06-09 Zeneca Limited Therapeutic agents for the treatment of cachexia
US5597843A (en) * 1995-06-07 1997-01-28 Houghten Pharmaceuticals Use of a substituted 1,3-benzodioxole to reduce a wasting condition
WO1997010822A1 (en) * 1995-09-21 1997-03-27 Eli Lilly And Company SELECTIVE β3 ADRENERGIC AGONISTS
WO1997010825A1 (en) * 1995-09-21 1997-03-27 Eli Lilly And Company SELECTIVE β3 ADRENERGIC AGONISTS
WO1998009625A1 (en) * 1996-09-05 1998-03-12 Eli Lilly And Company SELECTIVE β3 ADRENERGIC AGONISTS
WO1998020005A1 (en) * 1996-11-05 1998-05-14 Virbac S.A. Aryloxypropanolamine derivatives, method of preparation and applications thereof
WO1999029673A1 (en) * 1997-12-05 1999-06-17 Eli Lilly And Company SELECTIVE β3 ADRENERGIC AGONISTS
WO2000040560A1 (en) * 1998-12-30 2000-07-13 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1463219A (en) * 1974-04-03 1977-02-02 Roussel Uclaf Thyronamine derivatives
EP0140243A2 (en) * 1983-10-19 1985-05-08 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Phenoxypropanol amines
WO1994012166A1 (en) * 1992-11-26 1994-06-09 Zeneca Limited Therapeutic agents for the treatment of cachexia
US5597843A (en) * 1995-06-07 1997-01-28 Houghten Pharmaceuticals Use of a substituted 1,3-benzodioxole to reduce a wasting condition
WO1997010822A1 (en) * 1995-09-21 1997-03-27 Eli Lilly And Company SELECTIVE β3 ADRENERGIC AGONISTS
WO1997010825A1 (en) * 1995-09-21 1997-03-27 Eli Lilly And Company SELECTIVE β3 ADRENERGIC AGONISTS
WO1998009625A1 (en) * 1996-09-05 1998-03-12 Eli Lilly And Company SELECTIVE β3 ADRENERGIC AGONISTS
WO1998020005A1 (en) * 1996-11-05 1998-05-14 Virbac S.A. Aryloxypropanolamine derivatives, method of preparation and applications thereof
WO1999029673A1 (en) * 1997-12-05 1999-06-17 Eli Lilly And Company SELECTIVE β3 ADRENERGIC AGONISTS
WO2000040560A1 (en) * 1998-12-30 2000-07-13 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
COHEN MARLENE L ET AL: "Aryl propanolamines: Comparison of activity at human beta3 receptors, rat beta3 receptors and rat atrial receptors mediating tachycardia.", BRITISH JOURNAL OF PHARMACOLOGY, vol. 126, no. 4, February 1999 (1999-02-01), pages 1018 - 1024, XP001015387, ISSN: 0007-1188 *

Also Published As

Publication number Publication date
WO2001035947A2 (en) 2001-05-25
AU1572701A (en) 2001-05-30

Similar Documents

Publication Publication Date Title
WO2001035947A3 (en) Treating wasting syndromes with aryloxy propanolamines
NZ305133A (en) Tricyclic compounds, preparation and pharmaceutical compositions thereof
LU91196I2 (en) Picoxystrobin and its pharmaceutically acceptable derivatives (ACANTO).
WO2002026706A3 (en) 17-beta-hydroxysteroid dehydrogenase-ii inhibitors
DE60129210D1 (en) CYCLIC AMID DERIVATIVES
AR014868A1 (en) A COMPOUND DERIVED FROM N, N (REPLACED) PHENYL (ARYL OR HETEROARILE) PROPANAMINE, A PHARMACEUTICAL COMPOSITION, USE OF THE SUCH COMPOUND AND A METHOD TO PREPARE IT.
MY113208A (en) Pharmaceutical and compositions inhibiting kinases
EP1243583A4 (en) Heterocyclic compounds having sulfonamide groups
ATE231149T1 (en) (1,8)-NAPHTHYRIDINE DERIVATIVES DERIVATIVES WITH ANTIVIRAL EFFECT
MY104850A (en) N-phenyloyrazole derivatives
MXPA02006329A (en) Substituted 8arylquinoline phosphodiesterase4 inhibitors.
WO2001046166A3 (en) Partially saturated calcium channel blockers
AU598229B2 (en) Novel indenothiazole derivatives and process for their preparation
WO2002086143A3 (en) Enzymatic process for preparing cephalosporin derivatives
JPS57192339A (en) Isoprenylamine derivative
DK552682A (en) METHOD OF PREPARING HYDROXYBENZYLAMINOBENZENES
HUP0001245A1 (en) Novel erythromycin derivatives, method of preparation and application as medicines
AU6594900A (en) Tricyclic dihydrobenzofuran derivatives, process for the preparation thereof andagents
WO2000071551A3 (en) Purification of an organometallic compound by recrystallization
WO2001083479A3 (en) Process for the preparation of pyrazolopyridine derivatives
JPS5283818A (en) Novel cyclohexane derivatives
EP1238974A4 (en) Heterocycle derivatives and drugs
EP1043320A4 (en) New process for producing aminopiperazine derivatives
EP0753514A4 (en) Alkylenediamine derivative
EP1038876A3 (en) 1,2-Dioxetane derivative fused to pyran ring and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase